Data Analysis Legend (adopted from de Loe 1995)¹

CONSENSUS—A measure of the degree to which the group was able to agree on *support* (strong, weak etc).

High	70% of ratings in 1 category, or 80% in 2 contiguous categories
Med	60% of ratings in 1 category, or 70% in 2 contiguous categories
Low	50% of ratings in 1 category, or 60% in 2 contiguous categories

SUPPORT—Support indicates where the group's support lay when there was *consensus*. Categories include:

SS—Strong support

SS-ws—Strong, to weak support

ws—Weak support

WS-wo: Weak support to weak opposition

WO—Weak opposition

wo-SO: Weak, to strong opposition

SO—Strong opposition

When consensus is 'none', support is always 'ambiguous'. It can also be 'ambiguous' when:

- (1) the level of consensus is 'low' and the ratings are divided equally between two categories (e.g. rating distributions of 10 0 0 10, or 10 0 10 0);
- (2) the ratings are distributed in a pattern such as: 4 10 4 2. In this case, consensus would be considered 'medium' but the point of support could be either of 'SS-WS' or 'WS-WO'.

POLARITY*—Measures whether the group's ratings were polarized (e.g. 10 0 0 10 is a strongly polarized distribution). Categories include strong, weak, none. Polarity is determined using the variance of the distribution.

	De Loe 1995	Rahimzadeh 2018				
Strong	Higher than 1.5	Higher than 1.1				
Weak	Between 1.2 and 1.5	Between 0.8976 and 1.1				
None	Less than 1.2	Less than 0.8976				

^{*}modified from de Loe; transformed 80th percentile categories based on highest variance of the distribution calculated in the Round 1 dataset (1.122)

	DIMENSION	R	RATING		•	CONSENSUS	SUPPORT	POLARITY
		1	2	3	4			
1. The best interest of children are primary	Relative Importance	7	2	1	0	High	Strong support	None (0.488)
	Feasibility	2	6	2	0	High	Strong to Weak support	None (0.444)
2. Children should be listened to, and involved in	Desirability	1	8	1	0	High	Weak support	None (0.222)
decision-making processes related to genomic and associated clinical data sharing in developmentally appropriate ways	Feasibility	0	7	3	0	High	Weak support	None (0.233)
3. Parents should be informed in a transparent	Relative Importance	8	2	0	0	High	Strong support	None (0.177)
manner how their child's genomic and associated clinical data will be securely managed and used.	Confidence	1	7	2	0	High	Weak support	None (0.322)
4. In a research context, data sharing infrastructures should enable children to	Desirability	2	8	0	0	High	Strong support to weak support	None (0.177)
withdraw consent to continued sharing of their genomic and associated clinical data when possible upon reaching the age of majority.	Feasibility	1	2	7	0	High	Weak opposition	None (0.488)
5. Parental authorization for ongoing, or future unspecified research should include the provision	Relative Importance	6	2	2	0	High	Strong support to weak support	None (0.711)
of information related to existing data governance.	Desirability	5	4	0	1	High	Strong support to weak support	Weak (0.9)
	Relative Importance	5	3	2	0	High	Weak support	None (0.677)
6. Values conveyed by family, legal guardians or primary care givers should be respected when possible.	Feasibility	2	2	4	2	Low	Weak opposition	Strong (1.155)
7. All professionals involved in processes of data sharing and data-intensive research have the	Desirability	5	3	1	1	High	Strong support to weak support	Weak (1.06)
responsibility to balance potential benefits and risks and discuss these with parents at the time of consent.	Feasibility	2	4	2	2	Low	Weak support- weak opposition	None (0.5)
8. The decision to share pediatric genomic and	Feasibility	6	3	1	0	High	Strong support	None (0.5)
associated clinical data should be supported by an evaluation of realistic risks and benefits.	Confidence	4	5	1	0	High	Weak support	None (0.455)

9. Duplicative collection of genomic research data involving pediatric patients should be avoided.	Desirability	6	3	1	0	High	Strong to weak support	None (0.5)
	Feasibility	0	7	2	1	High	Weak support- weak opposition	None (0.488)
10. Anonymized pediatric data should be made available via publicly accessible databases.	Desirability	4	3	2	1	High	Weak support to weak opposition	Strong (1.11)
	Feasibility	3	4	3	0	High	Weak support to weak opposition	None (0.66)
11. Identifiable pediatric genomic and associated	Desirability	7	1	1	1	High	Strong support	Strong (1.115)
clinical data should be coded and made available through a controlled or registered access process.	Feasibility	4	5	0	1	High	Weak support	Weak (0.844)
12. Providing children and their parents the opportunity to share genomic and associated clinical data is an obligation of those who generate	Desirability	4	3	2	1	High	Strong support to weak support	Strong (1.11)
such data.	Feasibility	3	2	4	1	Low	Weak opposition	Strong (1.122)